ALPHA PHARMA is responsible for pharmacovigilance enforcement and ensuring compliance of pharmacovigilance system for Neotranex 500mg #5, Neocebron 500mg #5, Neocebron 1000mg #3, Parafusiv 1000mg/100ml #10, Tafixyl 500mg #30 in accordance with the requirements of the current legislation of Ukraine.
Pharmacovigilance is a process related to the detection, collection, evaluation, study and prevention of adverse reactions and any other issues related to the safety and effectiveness of the use of medicinal products.

The main goal of the pharmacovigilance system is to spread the necessary knowledge about adverse reactions among the public, to establish an algorithm of actions in the event of adverse reactions, to promote trust between the patient and the doctor, to substantiate the need for careful and correct use of drugs and to avoid self-medication of serious conditions.

Pharmacognosy includes the following concepts:
lack of effectiveness of the medicinal product - lack of favorable diagnostic, therapeutic or prophylactic effect of the medicinal product in determining the nature of the disease, its course, duration or correction of the condition or physiological functions of the human body in accordance with the indications for use specified in the instructions for medical use.

adverse reaction - any unintended and harmful reaction to a medicinal product.

series number – a characteristic combination of numbers and/or letters that specifically identifies the series. It is applied to all types of packaging.
If you noticed an unwanted or side effects,
if you have become aware of information about adverse reactions or the lack of effectiveness of Neotranex, Neocebron, Parafusiv, Tafixyl drugs, please inform us in a convenient way for you:
1. Send information through email: This email address is being protected from spambots. You need JavaScript enabled to view it.
2. Report by phone +380675686896, +380674670656, +380954240564
3. Fill out the online form on our website.
The information, that has been provided by you, is strictly confidential and it is not subject to disclosure, except for cases established by law.